Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Final draft guidance

Final appraisal document (PDF 189 KB)

Public committee slides (PDF 1.11 MB)

Final scope (PDF 240 KB)

Final stakeholder list (PDF 236 KB)

Equality impact assessment (Scoping) (PDF 128 KB)

Draft scope post referral (PDF 262 KB)

Final appraisal document - TA619 (PDF 286 KB)

Committee papers - TA619 (PDF 7.6 MB)

Public committee slides - TA619 (PDF 3.22 MB)

Final appraisal document - managed access agreement - TA619 (PDF 381 KB)

Equality impact assessment - TA619 (PDF 123 KB)

Final scope - TA619 (PDF 350 KB)

Final stakeholder list - TA619 (PDF 234 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA619 (PDF 185 KB)